Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 68, Issue 1, 2014, Pages 21-36

  Altamura, A Carlo ^a   Buoli, Massimiliano ^a   Pozzoli, Sara ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

bipolar disorder; immuno inflammatory system; neurodegenerative hypotheses; neurodevelopment; schizophrenia

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MINOCYCLINE; POLYUNSATURATED FATTY ACID; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR;

AUTOIMMUNE THYROIDITIS; BIPOLAR DISORDER; DISEASE ASSOCIATION; HEREDITY; HORMONAL REGULATION; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFLAMMATION; NERVE CELL DIFFERENTIATION; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; BRAIN; COMPARATIVE STUDY; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY;

BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; SCHIZOPHRENIA;

EID: 84891833079     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12089     Document Type: Review

References (167)

1. Altamura AC, Buoli M, Serati M,. Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders. Neuropsychiatry. 2011; 1: 81-90.
2. Kunz M, Ceresér KM, Goi PD, et al. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: Differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011; 33: 268-274.
3. Murray RM, Sham P, Van Os J, Zanelli G, Cannon M, McDonald C,. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr. Res. 2004; 71: 405-416.
4. Niculescu AB, Lulow LL, Odgen CA, et al. PhenoChipping of psychotic disorders: A novel approach for deconstructing and quantitating psychiatric phenotypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006; 141: 653-662.
5. Craddock N, Owen MJ,. Rethinking psychosis: The disadvantages of a dichotomous classification now outweigh the advantages. World psychiatry. 2007; 6: 84-91.
6. Altamura AC, Pozzoli S, Fiorentini A, Dell'Osso B,. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog. Neuropsychopharmacol Biol. Psychiatry 2013; 42: 63-70.
7. Weizman R, Bessler H,. Cytokines: Stress and immunity: An overview. In: Plotnikoff, NP, Faith, RE, Murgo, AJ, Good, RA, (eds). Cytokines, Stress and Immunity. CRC Press, Boca Raton, 1998; 1-15.
8. Kronfol Z, Remick DG,. Cytokines and the brain: Implications for clinical psychiatry. Am. J. Psychiatry 2000; 157: 683-694.
9. Kim YK, Jung HG, Myint AM, Kim H, Park SH,. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007; 104: 91-95.
10. Maier SF, Watkin LR,. Cytokines for psychologists: Implication of bidirectional immune-to-brain communication for understanding behaviour, mood and cognition. Psychol. Rev. 1998; 105: 83-107.
11. Schaefer M, Schmidt F, Neumer R, Scholler G, Schwarz M,. Interferon-alpha, cytokines and possible implications for mood disorders. Bipolar Disord. 2002; 4: 111-113.
12. Breder CD, Dinarello CA, Saper CB,. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240: 321-324.
13. Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CB,. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J. Comp. Neurol. 1993; 337: 543-567.
14. McGeer PL, McGeer EG,. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. 1995; 21: 195-218.
15. Schiepers OJ, Wichers MC, Maes M,. Cytokines and major depression. Prog. Neuropsychopharmacol Biol. Psychiatry 2005; 29: 201-217.
16. Aloisi F, Borsellino G, Caré A, et al. Cytokine regulation of astrocyte function: In-vitro studies using cells from the human brain. Int. J. Dev. Neurosci. 1995; 13: 265-274.
17. Muñoz-Fernández MA, Fresno M,. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog. Neurobiol. 1998; 56: 307-340.
18. Anisman H, Merali Z,. Cytokines, stress, and depressive illness. Brain Behav. Immun. 2002; 16: 513-524.
19. Schimtz T, Chew LJ,. Cytokines and myelination in the central nervous system. Scientific World Journal 2009; 8: 1119-1147.
20. O'Brien SM, Scully P, Scott L, Dinan TG,. Cytokines profiles in bipolar affective disorder: Focus on acutely ill patients. J. Affect. Disord. 2006; 90: 263-267.
21. Garver DL, Tamas RL, Holcomb JA,. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharm. 2008; 28: 1515-1520.
22. Potvin S, Stip E, Sephery AA, Gendron A, Bah R, Kouassi E,. Inflammatory cytokines alterations in schizophrenia: A systematic quantitative review. Biol. Psychiatry 2008; 63: 801-808.
23. Anderson G, Berk M, Dodd S, et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2013; 42: 1-4.
24. Krause D, Matz J, Weidinger E, et al. The association of infectious agents and schizophrenia. World J. Biol. Psychiatry 2010; 11: 739-743.
25. Torrey EF, Bartko JJ, Lun ZR, Yolken RH,. Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis. Schizophr. Bull. 2007; 33: 729-736.
26. Schwarcz R, Hunter CA,. Toxoplasma gondii and schizophrenia: Linkage through astrocyte-derived kynurenic acid? Schizophr. Bull. 2007; 33: 652-653.
27. Nyffeler M, Meyer U, Yee BK,. Maternal immune activation during pregnancy increases limbic GABA A receptor immunoreactivity in the adult offspring: Implications for schizophrenia. Neuroscience 2007; 143: 51-62.
28. Mortensen PB, Pedersen CB, McGrath JJ, et al. Neonatal antibodies to infectious agents and risk of bipolar disorder: A population-based case-control study. Bipolar Disord. 2011; 13: 624-629.
29. Tedla Y, Shibre T, Ali O, et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: A case-control study. Ethiop. Med. J. 2011; 49: 211-220.
30. Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J. Affect. Disord. 2013; 148: 444-448.
31. Pearce BD, Kruszon-Moran D, Jones JL,. The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol. Psychiatry 2012; 72: 290-295.
32. Machõn RA, Mednick SA, Huttunen MO,. Adult major affective disorder after prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 1997; 54: 322-328.
33. Pavuluri MN, Smith M,. A neuroimmune hypothesis for the aetiopathology of viral illness and manic depression: A case report of an adolescent. J. Affect. Disord. 1996; 39: 7-11.
34. Gorwood P, Pouchot J, Vinceneux P, et al. Club Rhumatisme et Inflammation. Rheumatoid arthritis and schizophrenia: A negative association at a dimensional level. Schizophr. Res. 2004; 66: 21-29.
35. Vonk R, van der Schot AC, Kahn RS, et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol. Psychiatry 2007; 62: 135-140.
36. Dean OM, Data-Franco J, Giorlando F, Berk M,. Minocycline: Therapeutic potential in psychiatry. CNS Drugs. 2012; 26: 391-401.
37. Di Nicola M, Cattaneo A, Hepgul N, et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2013; 31: 90-95.
38. McGrath JJ, Féron FP, Burne TH, Mackay-Sim A, Eyles DW,. The neurodevelopmental hypothesis of schizophrenia: A review of recent developments. Ann. Med. 2003; 35: 86-93.
39. Lake CR, Hurwitz N,. Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease-there is no schizoaffective disorder. Curr. Opin. Psychiatry 2007; 20: 365-379.
40. Schneider MR, DelBello MP, McNamara RK, Strakowski SM, Adler CM,. Neuroprogression in bipolar disorder. Bipolar Disord. 2012; 14: 356-374.
41. Roybal DJ, Singh MK, Cosgrove VE, et al. Biological evidence for a neurodevelopmental model of pediatric bipolar disorder. Isr. J. Psychiatry Relat. Sci. 2012; 49: 28-43.
42. Deverman BE, Patterson P,. Cytokines and CNS development. Neuron 2009; 64: 61-77.
43. Gilmore JH, Jarskog LF,. Exposure to infection and brain development: Cytokines in the pathogenesis of schizophrenia. Schizophr. Res. 1997; 24: 365-367.
44. Dammann O, Leviton A,. Maternal intrauterine infection, cytokines and brain damage in the preterm newborn. Ped. Res. 1997; 42: 1-8.
45. Brown AS, Derkits EJ,. Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am. J. Psychiatry 2010; 167: 261-280.
46. Jonakait GM,. The effects of maternal inflammation on neuronal development: Possible mechanisms. Int. J. Dev. Neurosci. 2007; 25: 415-425.
47. Schwarz MJ, Muller N, Riedel M Ackenheil M,. The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 2001; 56: 483-486.
48. Monji A, Kato T, Kanba S,. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009; 63: 257-265.
49. Patterson PH,. Immune involvement in schizophrenia and autism. Etiology, pathology and animal models. Behavioural Brain Research. 2009; 204: 313-321.
50. Elovitz MA, Mrinalini C, Sammel MD,. Elucidating the early signal transduction pathways leading to fetal brain injury in preterm birth. Pediatr. Res. 2006; 59: 50-55.
51. Altamura AC, Boin F, Maes M,. HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotics treatment. Eur. Neuropsychopharmacol. 1999; 10: 1-4.
52. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003; 60: 443-456.
53. Saji F, Samejima Y, Kamiura S, Sawai K, Shimoya K, Kimura T,. Cytokine production in chorioamnionitis. J. Reprod. Immunol. 2000; 47: 185-196.
54. Baud O, Emilie D, Pelletier E, et al. Amniotic fluid concentrations of interleukin-1beta, interleukin-6, and TNF-alpha in chorioamnionitis before 32 weeks of gestation: Histological association and neonatal outcome. Br. J. Obstet. Gynaecol. 2000; 106: 72-77.
55. Leonard BE, Song C,. Stress, depression, and the role of cytokines. Adv. Exp. Med. Biol. 1999; 461: 251-265.
56. Watkins LR, Nguyen KT, Lee JE, Maier SF,. Dynamic regulation of proinflammatory cytokines. Adv. Exp. Med. Biol. 1999; 461: 153-178.
57. Maes M, Song C, Lin A, et al. The effects of psychological stress on humans: Increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-318.
58. Goebel MU, Mills PJ, Irwin MR, Ziegler MG,. Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: Differential effects and pathways. Psychosom. Med. 2000; 62: 591-598.
59. Deinzer R, Granrath N, Stuhl H, et al. Acute stress effects on local Il-1beta responses to pathogens in a human in vivo model. Brain Behav. Immun. 2004; 18: 458-467.
60. Coe CL, Lubach GR,. Prenatal origins of individual variation in behaviour and immunity. Neurosci. Behav. Rev. 2005; 29: 39-49.
61. Merlot E, Couret D, Otten W,. Prenatal stress, fetal imprinting and immunity. Brain Behav. Immun. 2008; 22: 42-51.
62. Shen Q, Li ZQ, Sun Y, et al. The role of pro-inflammatory factors in mediating the effects on the fetus of prenatal undernutrition: Implications for schizophrenia. Schizophr. Res. 2008; 99: 48-55.
63. Connor CM, Crawford BC, Akbarian S,. White matter neuron alterations in schizophrenia and related disorders. Int. J. Dev. Neurosci. 2011; 29: 325-334.
64. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B,. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009; 59: 123-129.
65. Muller N, Schwarz M,. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 2006; 10: 131-148.
66. Müller N, Myint AM, Schwarz MJ,. Kynurenine pathway in schizophrenia: Pathophysiological and therapeutic aspects. Curr. Pharm. Des. 2011; 17: 130-136.
67. Yao JK, Dougherty GG Jr, Reddy RD, et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry 2010; 15: 938-935.
68. Condray R, Dougherty GG Jr, Keshavan MS, et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 2011; 14: 756-767.
69. Ganguli R, Brar JS, Rabin BS,. Immune abnormalities in schizophrenia. Evidence for the autoimmune hypothesis. Harv. Rev. Psychiatry 1994; 2: 70-83.
70. Zhang XY, Zhou DF, Cao LY, et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004; 65: 940-947.
71. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS,. Inflammation and the phenomenology, pathophysiology, comorbidity and treatment of bipolar disorder: A systematic review of the literature. J. Clin. Psychiatry 2009; 70: 1078-1090.
72. Muller N, Riedel M, Ackenheil M, Schwarz MJ,. The role of immune function in schizophrenia: An overview. Eur. Arch. Psychiatry Clin. Neurosci. 1999; 249: 62-68.
73. Mundo E, Altamura AC, Vismara S, et al. MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005; 132: 1-4.
74. Jablensky A,. Epidemiology of schizophrenia: The global burden of disease and disability. Eur. Arch. Psychiatry Clin. Neurosci. 2000; 250: 274-285.
75. Stöber G, Ben-Shachar D, Cardon M, et al. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J. Biol. Psychiatry 2009; 10: 127-155.
76. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK,. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 1998; 87: 129-136.
77. Kaminska T, Wyoska A, Marmurowska-Michalowska H,. Investigation of serum cytokines levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. (Warsz.) 2001; 29: 439-445.
78. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN,. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and their biological relatives. Schizophr. Res. 2006; 84: 180-182.
79. Naudin J, Mege JL, Azorin JM, Dassa D,. Elevated circulating levels of IL-6 in schizophrenia: An overview. Eur. Arch. Psychiatry Clin. Neurosci. 1996; 20: 269-273.
80. Naudin J, Capo C, Giusano B, Mège JL, Azorin JM,. Elevated circulating levels of interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr. Res. 1997; 26: 227-233.
81. Lin A, Kenis G, Bignotti S, et al. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr. Res. 1998; 32: 9-15.
82. Watanabe Y, Someya T, Nawa H,. Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010; 64: 217-230.
83. Smith RS, Maes M,. The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence. Med. Hypotheses 1995; 45: 135-141.
84. Drexhage RC, Knijff EM, Padmos RC, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010; 10: 59-76.
85. Kim YK, Myint AM, Lee BH, et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 1129-1134.
86. Müller N, Riedel M, Ackenheil MV, et al. Cellular and humoral immune system in schizophrenia: A conceptual re-evaluation. World J. Biol. Psychiatry 2000; 1: 173-179.
87. Schwarz MJ, Riedel M, Ackenheil M, Müller N,. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry 2000; 47: 29-33.
88. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM,. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol. 1997; 159: 2994-2999.
89. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B,. Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol. Psychiatry 2011; 70: 663-671.
90. Reale M, Patruno A, De Lutiis MA, et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci. 2011; 12: 13.
91. Zakharyan R, Boyajyan A, Arakelyan A, Melkumova M, Mrazek F, Petrek M,. Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population. Cytokine 2012; 58: 351-354.
92. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D,. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012; 37: 1901-1911.
93. Teixeira AL, Reis HJ, Nicolato R, et al. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2008; 32: 710-714.
94. Steiner J, Jacobs R, Panteli B, et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur. Arch. Psychiatry Clin. Neurosci. 2010; 260: 509-518.
95. van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE,. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr. Res. 2012; 141: 153-161.
96. Yao JK, van Kammen DP,. Membrane phospholipids and cytokine interaction in schizophrenia. Int. Rev. Neurobiol. 2004; 59: 297-326.
97. Akhondzadeh S, Tatabase M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B,. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr. Res. 2006; 84: 180-118.
98. Laan W, Grobbee DE, Selte JP, Heijnen CJ, Kahn RS, Burger H,. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010; 71: 520-527.
99. Muller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpiride treatment. Schizophr. Res. 2010; 121: 118-124.
100. Sublette ME, Russ MJ, Smith GS,. Evidence for a role of the arachidonic acid cascade in affective disorders: A review. Bipolar Disord. 2004; 6: 95-105.
101. Tang B, Capitao C, Dean B, Thomas EA,. Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Res. 2012; 196: 201-206.
102. Yao JK, Keshavan MS,. Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid. Redox Signal. 2011; 15: 2011-2035.
103. Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU,. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 2004; 50: 54-56.
104. Vitek L, Lenicek M, Jirsa M, et al. Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Res. 2010; 178: 449-450.
105. Yao JK, Reddy R, van Kammen DP,. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998; 80: 29-39.
106. Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrovic̈ B, Buzina R,. Vitamin C status in schizophrenia. Biol. Psychiatry 1990; 28: 959-966.
107. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A,. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol Biol. Psychiatry 2009; 33: 1178-1183.
108. Brown K, Reid A, White T, et al. Vitamin E, lipids, lipid peroxidation product and tardive dyskinesia. Biol. Psychiatry 1998; 43: 863-867.
109. Minutolo G, Petralia A, Dipasquale S, Aguglia E,. Nitric oxide in patients with schizophrenia: The relationship with the severity of illness and the antipsychotic treatment. Expert Opin. Pharmacother. 2012; 13: 1989-1997.
110. Zhang XY, Zhou DF, Shen YC, et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012; 62: 1928-1934.
111. Ryan MC, Sharifi N, Condren R, Thakore JH,. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 2004; 29: 1065-1070.
112. Shrivastava A, Johnston M, Bureau Y, Shah N,. Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: Is it a predictive factor? Innov. Clin. Neurosci. 2012; 9: 17-21.
113. Harris LW, Guest PC, Wayland MT, et al. Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology 2013; 38: 752-766.
114. Akiibinu MO, Ogundahunsi OA, Ogunyemi EO,. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 2012; 5: 169.
115. Smiths RS,. The macrophage theory of depression. Med. Hypotheses 1991; 35: 298-306.
116. Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. Peripheral biomarkers and illness activity in bipolar disorder. J. Psychiatr. Res. 2011; 45: 156-161.
117. Maes M, Delange J, Ranjan R, et al. Acute phase proteins in schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Res. 1997; 66: 1-11.
118. Rao JS, Harry GJ, Rapoport SI, Kim HW,. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010; 15: 384-392.
119. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: Phasic differences. Bipolar Disord. 2007; 9: 596-602.
120. Kupka RW, Breunis MN, Knijff E, Ruwhof C, Nolen WA, Drexhage HA,. Immune activation, steroid resistancy and bipolar disorder. Bipolar Disord. 2002; 2: 73-74.
121. Brietzke E, Sterz L, Fernandes BS, et al. Comparison of cytokines levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 2009; 116: 214-217.
122. Kim KW, Jun TY, Pae CU, et al. Association study of tumor necrosis-alpha gene polymorphism in schizophrenia and bipolar disorder. J. Korean Neuropsychiatr. Association. 2003; 42: 559-563.
123. Czerski PM, Rybakowski F, Kapelski P, et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008; 57: 88-94.
124. Padmos RC, Hillegers MHJ, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008; 65: 395-407.
125. Altamura AC, Mundo E, Cattaneo E, et al. The MCP-1 gene (SCYA2) and mood disorders: Preliminary results of a case-control association study. Neuroimmunomodulation 2010; 17: 126-131.
126. Middle F, Jones I, Robertson E, Lendon C, Craddock N,. Tumor necrosis factor alpha and bipolar affective puerperal psychosis. Psychiatr. Genet. 2000; 10: 195-198.
127. Meira-Lima IV, Pereira AC, Mota GF, et al. Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: Further support for an association with schizophrenia. Mol. Psychiatry 2003; 8: 718-720.
128. Padmos RC, Van Baal GC, Vonk R, et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: A twin study. Arch. Gen. Psychiatry 2009; 66: 957-965.
129. Jones KA, Porjesz B, Almasy L, et al. Linkage and linkage disequilibrium of evoked EEG oscillations with CHRM2 receptor gene polymorphisms: Implications for human brain dynamics and cognition. Int. J. Psychophysiol. 2004; 53: 75-90.
130. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Behav. Rev. 2011; 35: 804-817.
131. Robinson LJ, Ferrier N,. Evolution of cognitive impairment in bipolar disorder: A systematic review of cross-sectional evidence. Bipolar Disord. 2006; 8: 103-116.
132. Myint AM, Kim YK, Verkerk R, et al. Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord. 2007; 102: 65-72.
133. Kim SJ, Lee HJ, Koo HG, et al. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr. Genet. 2004; 14: 165-167.
134. Barbosa IG, Rocha NP, Bauer ME, et al. Chemokines in bipolar disorder: Trait or state? Eur. Arch. Psychiatry Clin. Neurosci. 2013; 263: 159-165.
135. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F,. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav. Immun. 2009; 23: 1079-1082.
136. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA,. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav. Immun. 2011; 25: 1206-1213.
137. Cassidy F, Wilson WH, Carroll BJ,. Leukocytosis and hypoalbuminemia in mixed bipolar states: Evidence for immune activation. Acta Psychiatr. Scand. 2002; 105: 60-64.
138. Igarashi M, Ma K, Gao F, et al. Brain lipid concentrations in bipolar disorder. J. Psychiatr. Res. 2010; 44: 177-182.
139. McNamara RK, Jandacek R, Rider T, et al. Deficits in docosahexanoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 2008; 160: 285-299.
140. Kim HW, Rapoport SI, Rao J,. Altered arachidonic acid cascade enzymes in post-mortem brain from bipolar disorder patients. Mol. Psychiatry 2011; 16: 419-428.
141. Yumru M, Savas HA, Kalenderoglu A, Bulut M, Celik H, Erel O,. Oxidative imbalance in bipolar disorder subtypes: A comparative study. Prog. Neuropsychopharmacol Biol. Psychiatry 2009; 33: 1070-1074.
142. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M,. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J. Psychiatry Neurosci. 2009; 34: 263-271.
143. Raison CL, Capuron L, Miller AH,. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 2006; 27: 24-31.
144. Rybakowski JK, Twardowska K,. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J. Psychiatr. Res. 1999; 33: 363-370.
145. Valiengo LL, Soeiro-de-Souza MG, Marques AH, et al. Plasma cortisol in first episode drug-naïve mania: Differential levels in euphoric versus irritable mood. J. Affect. Disord. 2012; 138: 149-152.
146. Buoli M, Caldiroli A, Panza G, Altamura AC,. Prominent clinical dimension, duration of illness and treatment response in schizophrenia. Psychiatry Invest. 2012; 9: 354-360.
147. Abreu P, Llorente E, Hernández MM, González MC,. Interleukin-1 beta stimulates tyrosine hydroxylase activity in the median eminence. Neuroreport 1994; 5: 1356-1358.
148. Shcherbakova IV, Siryachenko TM, Mazaeva NA, Kaleda VG, Krasnolobova SA, Klyushnik TP,. Leukocyte elastase and autoanitbodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. World J. Biol. Psychiatry 2004; 5: 143-148.
149. Silver H,. Selective serotonin reuptake-inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin. Pharmacother. 2004; 5: 2053-2058.
150. Meyer U, Schwarz MJ, Müller N,. Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol. Ther. 2011; 132: 96-110.
151. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC,. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology. Schizophr. Res. 2002; 57: 247-258.
152. Fan X, Prostach C, Liu E, Freudenreich O, Henderson DC, Goff DC,. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007; 149: 267-271.
153. Hilmas C, Pereira EF, Alkondon M, et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: Physiopathological implications. J. Neurosci. 2001; 21: 7463-7473.
154. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R,. C-reactive protein is associated with the severity of cognitive impairment but not psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007; 93: 261-265.
155. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide. J. Psychiatr. Res. 2008; 42: 151-157.
156. De Luca V, Tharmalingam S, Kennedy JL,. Association study between the corticotrophin-releasing hormone receptor 2 gene and suicidality in bipolar disorder. Eur. Psychiatry 2007; 22: 282-287.
157. Papiol S, Rosa A, Gutiérrez B, et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J. Med. Genet. 2004; 41: 219-223.
158. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M,. Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol. 2002; 17: 175-179.
159. Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatr. Res. 2011; 45: 1608-1616.
160. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY,. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995; 29: 141-152.
161. Rybakowski JK,. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 2000; 33: 159-164.
162. Kubera M, Maes M, Kenis G, Kim YK, Lasoń W,. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 2005; 134: 251-258.
163. Maes M, Bocchio Chiavetto L,. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002; 54: 281-291.
164. Kim YK, Suh IB, Kim H,. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs. Mol. Psychiatry 2002; 7: 1107-1114.
165. Igue R, Potvin S, Bah R, et al. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog. Neuropsychopharmacol Biol. Psychiatry 2011; 35: 1695-1698.
166. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia; a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012; 26: 1185-1193.
167. Stolk P, Souverein PC, Wilting I, et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot. Essent. Fatty Acids 2010; 82: 9-14.